SUPRIYA Supriya Lifescience Q1 FY27 results (Apr–Jun 2026) and concall
Supriya Lifescience Limited reported a robust 31% YoY revenue growth to ₹190 crores in Q1 FY27, driven by strong demand. However, EBITDA declined 8.1% to ₹47 crores, with margins at 25%, primarily due to temporary water scarcity, which deferred ₹35 crores in sales, and increased power costs impacting EBITDA by ₹8 crores. The company launched new anesthetic products and commenced work on the Patalganga expansion, while reaffirming its FY27 revenue and margin guidance, expecting a recovery in subsequent quarters.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 31.0%, net profit down 31.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 166 | 186 | 184 | 145 | 200 +20% | 206 +11% | 277 +51% | 190 +31% |
| EBITDA | 65 | 66 | 68 | 52 | 73 +12% | 72 +9% | 98 +44% | 47 −10% |
| Net profit | 46 | 47 | 50 | 35 | 50 +9% | 50 +6% | 74 +48% | 24 −31% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
